On Sunday, Bahrain’s Ministry of Health announced positive results from two weeks of Sotrovimab use.
It is a new anti-viral therapy that has been approved for use on patients with severe attack of COVID-19.
Sotrovimab is developed by British pharmaceutical company, GlaxoSmithKline (GSK) and Vir Biotechnology, a clinical immunology therapy developer.